In 2024, Spain leads European Peptic Ulcer and GORD medicine sales with a value of $37.48 million PPP, followed by Germany at $32.06 million. Notably, Spain and Croatia saw an increase in sales, with Spain experiencing a 4.61% rise while Germany exhibited a decline of 4.01%. Austria and Greece also saw decreases of 8.61% and 5.25%, respectively. Denmark experienced the highest growth at 5.81% among Nordic countries, while Iceland, despite being the smallest market, posted a 4.65% increase. Over the past five years, the compound annual growth rate (CAGR) indicates stability with slight fluctuations across countries.
Looking ahead, future trends to monitor in the European Peptic Ulcer and GORD medicines market include potential market expansion in less saturated areas like Eastern Europe and market consolidation in Western Europe. Attention should also be paid to regulatory changes and innovations that could offer significant cost or efficacy advantages, potentially reshaping sales shares by country.
Top countries in Peptic Ulcer and Gastro-Oesophageal Reflux Diseases (GORD) Medicine Sales Share by Country (Million US Dollars PPP)
| # | 10 Countries | Percent | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Spain | 37.48 | 2023 | +0.88% | +4.61% | View data |
| 2 | 2 Germany | 32.06 | 2023 | -3.06% | -4.01% | View data |
| 3 | 3 Croatia | 13.23 | 2023 | +1.95% | +2.5% | View data |
| 4 | 4 Greece | 8.58 | 2023 | -8.94% | -5.25% | View data |
| 5 | 5 Czech Republic | 2.75 | 2023 | +2.03% | +0.82% | View data |
| 6 | 6 Norway | 1.56 | 2023 | -1.59% | +1.58% | View data |
| 7 | 7 Austria | 1.23 | 2023 | -15.36% | -8.61% | View data |
| 8 | 8 Denmark | 1.08 | 2023 | -1.92% | +5.81% | View data |
| 9 | 9 Slovakia | 1.01 | 2023 | +2.14% | +3.22% | View data |
| 10 | 10 Slovenia | 0.77 | 2023 | -1.61% | +1.25% | View data |
